WEST LAFAYETTE, Ind. — Extracting data from equipment can be an expensive and cumbersome process for farmers.To solve this problem, ISOBlue was launched to make precision agriculture data more available.
ISOBlue’s goal it to make data readily available through the use of a low-cost device that transfers information from the equipment’s ISOBUS to a smart phone.
Bluetooth connections on smart phones allow farmers, agronomists and others involved in production to see information in real time.
“It’s very expensive to get data that the machines generate,” said Jesse Vollmar, CEO and co-founder of FarmLogs. “As precision ag has developed we have realized the value of that data and how it can be applied to farms to increase yields.
“We also know it is too expensive to get access to it, so we decided to be one of the companies contributing to funding. Purdue’s students and faculty committed time to the project. It’s been successful thus far, and we want to expand the reach.”
ISOBlue is a brainchild of students at Purdue University. FarmLogs, an agricultural technology company, sponsored the project in efforts to develop cloud-based processing and data storage.
The hardware is designed to resist harsh conditions, including weather, dust, dirt and water.
Anyone interested in trying ISOBlue can participate.
“It’s an open-source project,” Vollmar said. “Any farmer that wants to can get involved and contribute.”
Currently, the ISOBlue project moves data to the smart phone, but does not interpret it. FarmLogs is in the process of creating a product that can display data instantly in a format that provides analysis.
With FarmLog’s integration of ISOBlue, unnecessary data, such as whether the brake lights are on, will not display. Only specific information, such as what seeds were planted where, soil moisture levels and more, will be appear.
The information will be easily transferrable among agronomists, tax accountants and others who the farmer wants to share data with.
“This is good for agriculture,” Vollmar said. “This is good for farmers. It’s making it lower cost to get access to data. We’re involved because we feel like farmers deserve that.
“We are going to take this and make it an off-the-shelf product where you can plug it in, set it and forget it. That’s coming in 2014. It’s a really exciting project that will make a big impact in agriculture.”
To learn more about ISOBlue, visit www.isoblue.org or www.farmlogs.com.
A Kalamazoo biotech company has appointed a new president/CEO and board director.
Tolera Therapeutics, a privately held immune therapy company developing a novel T-cell targeted therapeutic platform, has hired Ashleigh Palmer, president and founder of Creative BioVentures Corp.
While taking the lead at Tolera, Palmer will continue in his role at Creative BioVentures, a strategic advisory serving the biopharma industry.
Since founding Creative BioVentures in 2002, Palmer has undertaken several development stage and turnaround assignments, including CEO and chairman of Restoragen, CEO of Canfite Biopharma and CEO of Unigene Laboratories.
Tolera board chairman Suzette Dutch, a managing partner at Triathlon Medical Ventures, said Palmer “has an ideal track record in developing, partnering and commercializing advanced-stage biopharma assets and pioneering therapeutic platforms.”
Previously, Palmer was vice president of business development at Ohmeda, where he played an instrumental role in its $1.2-billion sale to a Baxter-led consortium, by spinning out Ohmeda’s inhaled nitric oxide assets to found INO Therapeutics.
Under Palmer’s leadership, INO developed and commercialized the world’s first selective pulmonary vasodilator, INOmax, establishing an orphan drug franchise subsequently acquired by Ikaria for $670 million.
Earlier in his career, Palmer held positions of increasing responsibility in sales and marketing management at Reckitt Benckiser and SSL International.
He received his M.B.A. from the University of Bradford, England and his B.S. with honors in biochemistry and applied molecular biology from the University of Manchester, England.
Tolera Therapeutics is focused on developing and commercializing a highly specific, T-cell antagonist, monoclonal antibody technology, anti-TCR, with application potential across a broad spectrum of T-cell mediated diseases, such as transplant rejection, autoimmune disease and cancer.
The company’s TOL101 has successfully completed clinical testing through Phase 2 and is ready for advanced stage clinical testing, having received approval of a special protocol assessment with the U.S. Food and Drug Administration for a Phase 3 clinical trial, comparing TOL101 to Thymoglobulin.
Tolera Therapeutics’ primary investors include Triathlon Medical Venture Partners, Hopen Life Science Ventures, the SWMF Life Science Fund and the Michigan Economic Development Corporation.
“Having completed a successful Phase 2 renal transplantation study for its lead product candidate, TOL101, Tolera is now poised to carefully consider its strategic options, evaluate the needs of prospective partners and advance this novel therapeutic approach towards a market that appears ripe for the entry of an advantageous induction agent,” Palmer said. “Tolera also has a significant opportunity to advance its broader T-cell targeting therapeutic platform, especially with respect to autoimmune disease and cancer. Effective partnering will be the key to this endeavor.”
Blue Medora updates Oracle EM12c plugin for VMware to support full lifecycle management of Oracle Databases and WebLogic J2EE on VMware.
Blue Medora, a software innovator in extending the technological reach and value of IT management platforms, today announced the latest release of the Blue Medora Oracle Enterprise Manager 12c (Oracle EM12c) Plugin for VMware. This newest advancement extends Oracle EM12c by enabling turnkey, full Oracle EM12c-based lifecycle Middleware-as-a-Service and Database-as-a-Service capabilities for Oracle customers that wish to use VMware as their virtualization platform for Development, test, and, production environments.
The Blue Medora EM12c plugin for VMware combined with the power of Oracle Enterprise Manager 12c and Self Service Portal, enables customers to easily consolidate, clone and manage many Oracle database and Oracle Weblogic J2EE instances on VMware, improving IT productivity by reducing the time needed to perform administrative tasks and providing the ability to quickly identify and resolve issues through comprehensive diagnostics and analysis capabilities.
“Oracle has done a tremendous job bringing innovative and incredibly productive DBaaS and MwaaS capabilities to market as part of Oracle EM12c — offering organizations very compelling benefits, including faster deployment, higher availability and lower operational complexity,” said Nathan Owen, CEO, Blue Medora. “With the new release of Blue Medora EM12c Plugin for VMware, customers can finally take full advantage of Oracle’s “as-a-service” capabilities using the industry’s most widely adopted virtualization platform, VMware.”
“Making Oracle’s Database and Middleware self-service capabilities, including provisioning, monitoring, backup, and enterprise grade scaling from one to hundreds of instances, available for VMware is huge for our customers who are looking for reduced IT Infrastructure costs and improved business agility.”, said Marlin McNeil, CTO at The Yucca Group, “the overlap of Oracle customers that run VMware as their primary virtualization platform is nearly 100%. We see the latest release of the Blue Medora EM12c plugin for VMware as removing what had, up to this point, been the last technological barrier to running, monitoring, and managing production Oracle workloads on VMware”.
The latest release of the Blue Medora EM12c plugin for VMware includes:
•New VMware-focused “management” target that adds integrated VMware provisioning to Oracle EM12c MwaaS and DBaaS
•The ability to create 1 to up to hundreds VMware-based Oracle Database or Oracle WebLogic J2EE instances that are fully integrated with Oracle EM12c immediately upon creation
•Integration of VMware based resources into the Oracle EM12c self service portal
•Adds support for the latest version of VMware vSphere – v5.5
Blue Medora specializes in increasing the value of leading IT infrastructure management platforms. Blue Medora has developed a range of validated/certified integration products that extend the monitoring and management capabilities of IBM, Oracle, and VMware’s market-leading systems management platforms to the world’s leading cloud, virtualization, ERP, CRM, enterprise directory, messaging software, and more.
For additional information, visit
For the original version on PRWeb visit:
Read more at:
Last week we mentioned that Ambiq Micro, a Zell Lurie startup that made the Poets Quants list of top 100 MBA Startups. In this blog post we wanted to share more about the company to shed light on their success.
Ambiq Micro’s connections to the University of Michigan began with their CTO and Vice President of Engineering, Scott Hanson, who is a graduate from UM’s College of Engineering. It’s connection with UM did not end there; when Ambiq Micro was getting started it received an early investment from the Frankel Fund, now the Zell Lurie Commercialization Fund.
Since then, Grand Angels recently announced its fifth funding commitment of 2013, investing in Ambiq Micro, a leader in ultra-low power integrated circuits. Grand Angels invested alongside venture capital firms Austin Ventures, ARM®, Mercury Fund, Huron River Ventures and other investors in the $10 million Series B funding round.
Ambiq Micro is an advanced semi-conductor company that uses their products for smart cards, wireless sensors, medical devices and more. They are currently developing SPOT, Subthreshold Power Optimized Technology, which will allow products to run at very low voltage rates, requiring less power.
TROUT CREEK VENTURes
A regional co-investment fund specializing in angel and early stage private equity.